Polymorphisms at IL28B gene as predictors of viral relapse in genotype 4 Egyptian hepatitis C patients

Abstract

Chronic HCV is one of the commonest causes of chronic liver disease worldwide with about 15% of population infected in Egypt. Certain single nucleotide polymorphisms (SNPs) lying near the IL28B gene were found to affect the spontaneous clearance as well as treatment outcome of HCV. To examine the association between different IL28B variants and the relapse of HCV infection after combined therapy with ribavirin and pegylated interferon (pegIFN). Hundered HCV genotype four patients received 1.5 mg/kg/week peginterferon alfa-2b plus 800-1400 mg/d ribavirin (weight-adjusted) for 48 weeks. IL28B polymorphisms (rs12980275, rs12979860, and 1 rs8099917) were studied in responders and relapsers at week 72. Out of 69 patients receiving treatment, 13 (18.8%) were relapsers. By stratifying patients on the basis of the IL-28/60 genotype (CC vs. CT/TT), CC patients showed lower relapse rates (2.3%) compared with CT/TT patients (46.2%) (P < 0.001). On the basis of the IL-28/75 genotype (GG vs. GA/AA), the GG patients achieved higher relapse rates (62.5%) compared with GA/AA patients (13.1%) (P = 0.004). Moreover, no statistical significant difference was observed between the TT patients compared with GG/GT patients on the basis of the IL-28/17 genotype. SNPs at IL-28/60 and IL-28/75 are possible predictors of relapse in patients receiving dual treatment.

Interferon-γ inducible protein-10 and interleukin 28B gene polymorphism as predictive markers for genotype 4 hepatitis C virus treatment response

“…Furthermore, our results revealed that, TT genotype of IL-28B (rs8099917) was the most common in the studied patients (44.0%) while GT genotype identified in 42% and GG was detected in 14.0%. In agreement with our study, Ragheb et al (2014) and Esmail et al (2016) found that TT genotype was the most common among their studied patients.…”

“…Similar result was reported with Hendy et al regarding AST and ALT levels. On the other hand, Esmail et al (2016) detected no significant difference of ALT and AST with IL28B rs8099917 genotypes.…”

Parallel expression profiling of hepatic and serum microRNA-122 associated with clinical features and treatment responses in chronic hepatitis C patients

“…The most notable example in this regard is IL-28B, whose polymorphisms have been reported to associate with ETR. However, the available IL-28B data is still somewhat conflicting 41 42 and to date, no universally applicable predictive marker of PEG-INF/RBV therapy has been established. Due to the significance of miR-122 in HCV infections, the association between hepatic miR-122 expression and ETR has been evaluated in some recent reports.…”

Interleukin-28B Polymorphism is a Pharmacogenetic Predictor during Sofosbuvir Plus Pegylated Interferon and Ribavirin Therapy for Chronic Hepatitis C Egyptian Patients

“…Recently, IL28B SNP, alpha fetoprotein level, and cytotoxic T-Lymphocytes antigen-4 (CTLA-4) SNP could be used in conjunction to predict treatment response in HCV-G4 infected Egyptian patients [30]. In addition, Esmail et al [31] demonstrated that IL-28B SNP polymorphism is considered as a vital predictor of viral relapse.…”